PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

Abstract

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)). Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Neuroblastoma; Diffuse Intrinsic Pontine Glioma Interventions: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)

Keywords

Sources